Pharmalittle: We're reading about a Novo setback, support for Replimune's melanoma drug, and more

An FDA advisory panel recently voted 10 to 3 in favor of an experimental melanoma treatment from Replimune. The committee determined that existing clinical data is sufficient for the agency to proceed with the review of RP1. This engineered viral immunotherapy previously faced rejection in both the prior year and this past April. Industry observers are now watching closely to see how the agency handles the risk and benefit profile for investigational drugs under its current leadership.

Simultaneously, the high-growth phase of the weight loss drug market appears to be cooling. Recent data from Cigna indicates that both employers and insurers are pulling back on coverage for these treatments. Slower utilization and a measurable decline in pharmacy benefit management growth suggest the sector is moving into a period of restraint. Approximately 6 percent of large employers discontinued coverage for weight loss medications this year, according to a recent survey.

These developments highlight a broader shift across the pharmaceutical industry. While innovation in cancer therapy continues to move toward regulatory milestones, the commercial landscape for lifestyle-focused drugs faces new pressure from plan sponsors and payers. We continue to monitor how these market signals impact long-term corporate strategies in the biotech sector.